Search Page

1

Cite

Share

Challenges and Opportunities for Biomarker Validation.

Hey SP, D'Andrea E, Jung EH, Tessema F, Luo J, Gyawali B, Kesselheim AS. Hey SP, et al. Among authors: tessema f. J Law Med Ethics. 2019 Sep;47(3):357-361. doi: 10.1177/1073110519876162. J Law Med Ethics. 2019. PMID: 31560620

Cite

Share

2

Cite

Share

Physician Perceptions of Step Therapy Prescribing Requirements.

Fischer MA, Kesselheim AS, Lu Z, Ross KM, Tessema FA, Avorn J. Fischer MA, et al. Among authors: tessema fa. J Manag Care Spec Pharm. 2019 Nov;25(11):1210-1224. doi: 10.18553/jmcp.2019.25.11.1210. J Manag Care Spec Pharm. 2019. PMID: 31663459

Cite

Share

3

Cite

Share

Public funding for transformative drugs: the case of sofosbuvir.

Barenie RE, Avorn J, Tessema FA, Kesselheim AS. Barenie RE, et al. Among authors: tessema fa. Drug Discov Today. 2021 Jan;26(1):273-281. doi: 10.1016/j.drudis.2020.09.024. Epub 2020 Oct 1. Drug Discov Today. 2021. PMID: 33011345 Free PMC article. Review.

Cite

Share

4

Cite

Share

Generic Competition for Drugs Treating Rare Diseases.

Beall RF, Quinn AE, Kesselheim AS, Tessema FA, Sarpatwari A. Beall RF, et al. Among authors: tessema fa. J Law Med Ethics. 2020 Dec;48(4):789-795. doi: 10.1177/1073110520979391. J Law Med Ethics. 2020. PMID: 33404340 No abstract available.

Cite

Share

5

Cite

Share

Physicians' Perspectives on FDA Approval Standards and Off-label Drug Marketing.

Kesselheim AS, Woloshin S, Lu Z, Tessema FA, Ross KM, Schwartz LM. Kesselheim AS, et al. Among authors: tessema fa. JAMA Intern Med. 2019 May 1;179(5):707-709. doi: 10.1001/jamainternmed.2018.8121. JAMA Intern Med. 2019. PMID: 30667474 Free PMC article.

Cite

Share

6

Cite

Share

Internal Medicine Physicians' Financial Relationships with Industry: An Updated National Estimate.

Kesselheim AS, Woloshin S, Lu Z, Tessema FA, Ross KM, Schwartz LM. Kesselheim AS, et al. Among authors: tessema fa. J Gen Intern Med. 2019 Feb;34(2):195-197. doi: 10.1007/s11606-018-4688-z. J Gen Intern Med. 2019. PMID: 30291605 Free PMC article. No abstract available.

Cite

Share

7

Cite

Share

US Spending Associated With Transition From Daily to 3-Times-Weekly Glatiramer Acetate.

Rome BN, Tessema FA, Kesselheim AS. Rome BN, et al. Among authors: tessema fa. JAMA Intern Med. 2020 Sep 1;180(9):1165-1172. doi: 10.1001/jamainternmed.2020.2771. JAMA Intern Med. 2020. PMID: 32897384

Cite

Share

8

Cite

Share

Changes in Erythropoiesis Stimulating Agent Use Under a Risk Evaluation and Mitigation Strategy (REMS) Program.

Sarpatwari A, He M, Tessema FA, Gagne JJ, Kesselheim AS. Sarpatwari A, et al. Among authors: tessema fa. Drug Saf. 2021 Mar;44(3):327-335. doi: 10.1007/s40264-020-01017-z. Epub 2020 Nov 18. Drug Saf. 2021. PMID: 33206339

Cite

Share

9

Cite

Share

Patients' Knowledge of Key Messaging in Drug Safety Communications for Zolpidem and Eszopiclone: A National Survey.

Kesselheim AS, Sinha MS, Rausch P, Lu Z, Tessema FA, Lappin BM, Zhou EH, Dal Pan GJ, Zwanziger L, Ramanadham A, Loughlin A, Enger C, Avorn J, Campbell EG. Kesselheim AS, et al. Among authors: tessema fa. J Law Med Ethics. 2019 Sep;47(3):430-441. doi: 10.1177/1073110519876176. J Law Med Ethics. 2019. PMID: 31560634

Cite

Share

10

Cite

Share

Assessing the Justification, Funding, Success, and Survival Outcomes of Randomized Noninferiority Trials of Cancer Drugs: A Systematic Review and Pooled Analysis.

Gyawali B, Tessema FA, Jung EH, Kesselheim AS. Gyawali B, et al. Among authors: tessema fa. JAMA Netw Open. 2019 Aug 2;2(8):e199570. doi: 10.1001/jamanetworkopen.2019.9570. JAMA Netw Open. 2019. PMID: 31469391 Free PMC article.

Cite

Share